Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. (CRMD) director reported an open‑market purchase of 25,000 shares of common stock on 10/23/2025 at a weighted average price of $11.02 (transactions ranged from $11.01 to $11.03), coded “P” for purchase.
Following the transaction, the reporting person beneficially owns 201,034 shares directly. The filing also lists 20,000 shares held indirectly by a spouse and 10,000 shares held indirectly as spouse acting as guardian for grandchildren; beneficial ownership of these indirect holdings is disclaimed.
CorMedix Inc. called a virtual special meeting on November 10, 2025 to seek stockholder approvals on five items affecting capital structure, equity incentives, and governance.
Proposal 1 asks stockholders to approve the “Exchange Cap Removal” under Nasdaq Rule 5635(a), permitting issuances above the 19.99% cap tied to the Company’s $150,000,000 convertible senior notes due 2030, the Melinta merger consideration, and potential contingent payments. The filing notes 3,323,833 Merger Shares were issued at closing, a current cap of 14,922,333 shares, a maximum of 14,479,035 shares upon note conversion if the cap is removed, and a request to approve up to 3,000,000 shares for contingent payments.
Proposal 2 seeks to amend the 2019 Omnibus Stock Incentive Plan to add 4,312,000 shares, increasing the plan reserve to 12,472,000 shares. Proposal 3 requests ratification under DGCL Section 204 of amendments to certificates of designation for preferred stock. Proposal 4 would amend the Certificate of Incorporation to allow preferred holders to vote on amendments relating solely to their series. Proposal 5 permits adjournment to solicit additional proxies if needed.
CorMedix Inc. (CRMD) amended its preliminary proxy for a virtual Special Meeting now set for November 10, 2025. The Amended Proxy adds two proposals and updates related materials, including naming a proxy solicitor.
Stockholders will vote on: (1) Exchange Cap Removal under Nasdaq Rule 5635(a) to permit issuances above the 19.99% cap tied to the Company’s $150,000,000 convertible senior notes due 2030 and its Melinta merger consideration; (2) an amendment to the 2019 Omnibus Plan to increase the share reserve by 4,312,000 (from 8,160,000 to 12,472,000); (3) ratification of certain preferred stock Certificate of Designation amendments under DGCL Section 204; (4) a charter amendment allowing preferred holders to vote on amendments relating solely to outstanding preferred series; and (5) adjournment, if needed.
For Proposal 1, the Company states 3,323,833 Merger Shares were issued at closing and seeks approval to permit up to 14,479,035 shares upon note conversion (per Indenture terms) and to issue up to 3,000,000 shares for potential contingent milestone consideration, with any excess consideration payable in cash.
CorMedix, Inc. (CRMD) filed an S-3ASR prospectus registering up to 6,323,833 shares of common stock to be sold by existing selling securityholders rather than by the company. The selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with Fund IV accounting for up to 4,853,542 shares (consisting of 2,551,042 merger-issued shares and up to 2,302,500 milestone shares) and Fund III accounting for up to 1,470,291 shares (consisting of 772,791 merger-issued shares and up to 697,500 milestone shares). Milestone shares are issuable under a contingent purchase agreement and will be valued using the five-day volume weighted average price on NASDAQ preceding each milestone date through June 30, 2029. The prospectus states the company will receive no proceeds from these sales and lists $140,000 of legal fees and expenses. The company's common stock trades on the Nasdaq Global Market under the symbol CRMD.
CorMedix, Inc. (CRMD) filed a shelf registration on Form S-3ASR to allow selling securityholders to offer up to 6,323,833 shares of common stock. The company will not receive proceeds from these sales. Principal selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with detailed allocations showing 2,551,042 and 772,791 shares issued under the Merger Agreement, plus potential 2,302,500 and 697,500 milestone shares issuable under a contingent purchase agreement (CPA) through June 30, 2029. Shares for milestones will be valued using the five-day VWAP before each milestone date. The prospectus references risk factors and incorporates the company Form 10-K for fiscal 2024 filed March 25, 2025. A listed legal fees line item shows $140,000.
CorMedix Inc. (CRMD) has a shelf prospectus for resale of up to 6,323,833 shares of common stock by selling securityholders; the company will not receive proceeds from those sales. The shares include amounts issued under a Merger Agreement and potential milestone shares issuable under a Collaboration and Purchase Agreement (CPA) through June 30, 2029, with milestone share valuation tied to a five-day VWAP on the Nasdaq prior to each milestone. Named selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with specified allocations of Merger and potential milestone shares. The Nasdaq Global Market ticker is CRMD. The prospectus refers investors to the Risk Factors section and incorporated reports for further details.
CorMedix Inc. filed Amendment No. 1 to a prior current report to provide additional financial information related to its completed acquisition of Melinta Therapeutics, LLC. The amendment relates to the merger that closed on August 29, 2025 under the Agreement and Plan of Merger dated August 7, 2025.
The filing adds audited consolidated financial statements of Melinta for the years ended December 31, 2024 and 2023, unaudited condensed consolidated financial statements for the six months ended June 30, 2025, and unaudited pro forma condensed combined financial information for the year ended December 31, 2024 and the six months ended June 30, 2025. These materials are included as Exhibits 99.2, 99.3 and 99.4, along with an auditor consent.
CorMedix Inc. director Gregory Scott Duncan reported insider transactions on 09/16/2025. The filing shows an acquisition of 13,333 shares of common stock at $8.32 per share, bringing his total common stock beneficially owned to 38,333 shares. The report also lists a derivative transaction showing 13,333 stock options with an $8.32 exercise price, exercisable beginning 01/10/2031, and 6,667 derivative shares beneficially owned following the transaction. The form notes these options were granted 01/11/2021 and vest monthly with full vesting after one year, subject to continued board service.
CorMedix Inc. director Gregory Scott Duncan reported insider transactions on 09/16/2025. The filing shows an acquisition of 13,333 shares of common stock at $8.32 per share, bringing his total common stock beneficially owned to 38,333 shares. The report also lists a derivative transaction showing 13,333 stock options with an $8.32 exercise price, exercisable beginning 01/10/2031, and 6,667 derivative shares beneficially owned following the transaction. The form notes these options were granted 01/11/2021 and vest monthly with full vesting after one year, subject to continued board service.